Daewoong Pharma Extends Nabota Plant 3 Investment End Date to May 2027, No Change in Investment Scale

Daewoong Pharma filed a correction disclosure extending the end date of its new facility investment from June 30, 2026 to May 31, 2027.
The adjustment reflects the GMP approval timeline for the pharmaceutical manufacturing facility's actual operation.
The investment amount of 101.36 billion KRW equivalent to 13.7% of equity remains unchanged with no impact on shareholder dilution or funding plans.
[AI Summary]This administrative amendment extends the project timeline without altering investment scale or financial terms, making it neutral for the stock. The core plan for Nabota production capacity expansion remains intact.